Vertex Pharmaceuticals (VRTX) Q1 FY26 earnings call: guidance and Q&A

What needs to happen for the renal franchise to rival CF in size, and which renal asset has the greatest long-term revenue potential?

Reshma Kewalramani explained that the renal franchise targets common rare diseases (IgAN, membranous, AMKD, ADPKD) with hundreds of thousands of patients in Western markets. The diseases lead to severe outcomes (death, dialysis, transplantation), and Pove and inaxaplin have shown transformative potential. She highlighted Pove in IgAN as currently looking "sparkling" due to recent Phase III results.

“The reason I think that this has the potential to be as big, if not larger, than CF is that the diseases that these medicines treat are rare diseases, but they are common rare diseases.”

asked by Jessica Fye · answered by Reshma Kewalramani

Discuss read-through from Maze's recent data to inaxaplin and whether enrollment enriched for patients with larger APOL1 contribution to CKD.

Reshma Kewalramani declined to comment directly on Maze's data but noted Vertex's inaxaplin Phase II showed a 47.6% proteinuria reduction compared to Maze's 35.6%. She affirmed the decision to study heterogeneous patient groups (moderate proteinuria, diabetes) in separate trials (AMPLIFIED), with results expected in H2 2026.

“What I will say is I'm very happy about the decision we made early on to not mix a heterogeneous group and to focus our program on those with heavy proteinuria, 2 APOL1 alleles and reduced kidney function and not study those who have a comorbid condition like diabetes.”

asked by Salveen Richter · answered by Reshma Kewalramani

How will Vertex differentiate Pove in IgAN against competitors and overcome first-mover advantage?

Duncan McKechnie emphasized the large market opportunity in IgAN (160,000 U.S. patients, 75% not at guideline goal). He highlighted Pove's "winning trifecta": rapid, deep, and sustained proteinuria reduction; favorable tolerability; and attractive monthly subcutaneous auto-injector dosing. Market research indicates preference for dual BAFF/APRIL inhibition and monthly dosing. Vertex's commercial capabilities in high-science selling, reimbursement, and patient support will be key.

“We think it has a sort of winning trifecta of incredible clinical effects, as you heard in the prepared remarks, things like the rapid, deep and sustained reduction in proteinuria, as well as Gd-IgA1 and hematuria. It has a supremely favorable tolerability profile and very attractive dosing and administration.”

asked by Brian Abrahams · answered by Duncan J. McKechnie

Is an IV modality needed for JOURNAVX in acute pain, and are other autoimmune indications suitable for Pove basket studies beyond pMN and gMG?

Reshma Kewalramani stated an IV modality for pain would be helpful, and Vertex is exploring formulatability into IV for its NaV1.8s and NaV1.7s. For Pove, she confirmed that basket studies are an efficient way to evaluate additional B-cell-mediated conditions where autoantibodies are important, beyond IgAN, pMN, and gMG.

“I do think a basket study is a very efficient way of evaluating those conditions through Phase II development.”

asked by Geoffrey Meacham · answered by Reshma Kewalramani

What level of clinical benefit is needed in the AMPLIFIED study (AMKD patients with moderate proteinuria or diabetes) to justify advancement?

Reshma Kewalramani indicated that a substantial double-digit improvement in proteinuria, specifically in the range of 20% to 40% (e.g., 30%), on top of standard of care, would be considered clinically meaningful for advancement.

“I would say if we can show a 30% improvement, some number between 20% and 40%, 25% and 50%, some substantial double-digit improvement in proteinuria on top of standard of care, of course, that would be meaningful.”

asked by Cory Kasimov · answered by Reshma Kewalramani

Will Pove show eGFR differentiation over time, and address concerns about hypogammaglobulinemia and its impact on Pove's safety?

Reshma Kewalramani clarified that GFR is a regulatory-enabling endpoint for full approval, but proteinuria is the most proximal reflection of hard endpoints like death/dialysis/transplantation. She emphasized Pove's favorable safety profile regarding infections (0.5% SAEs in both Pove and placebo groups) despite B-cell modulation, noting that varying thresholds for hypogammaglobulinemia across trials make cross-comparison difficult, but the infection profile is key.

“The important thing, though, Michael, is you're asking me, hey, is there anything there that gives you concern? None at all. The important thing to look at is the infections and the infections look very balanced between these groups.”

asked by Michael Yee · answered by Reshma Kewalramani

Reconcile Q1 JOURNAVX revenue with prescription volume, and explain if more employer/Tier 2 formulary positions are needed for gross-to-net normalization given current payer coverage.

Duncan McKechnie explained Q1 revenue ($29M) was impacted by normal channel inventory destocking, Medicare Part D resets, and a strong flu season affecting elective surgeries. He confirmed being on track to triple 2025 prescriptions. He stated that with 240 million lives covered and recent Medicare Part D agreements (2 secured, 1 close), no further focus on downstream plans is needed; gross-to-net will normalize by year-end, accelerating revenue faster than prescription growth.

“I don't think we need to be focused on downstream plans and employer plans. As we have said all along, as we secure the final pillars of access, the patient support program will taper down, our gross to net will normalize by the end of the year, and you will see revenue significantly accelerate and accelerate faster than prescription growth as we go through the balance of the year.”

asked by David Risinger · answered by Duncan J. McKechnie